CervoMed Inc. 8-K

What Happened
CervoMed Inc. (CRVO) filed an 8-K on March 19, 2026 (Item 7.01) disclosing a press release announcing new analyses from its Phase 2b RewinD‑LB clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB). Investigators will present these analyses in an oral session at the AD/PD™ 2026 Conference in Copenhagen on March 21, 2026. The press release is attached as Exhibit 99.1 and the company has posted presentation materials on its website under “Investors – Events and Presentations.”

Key Details

• Press release and disclosure filed on March 19, 2026; oral presentation scheduled for March 21, 2026 at AD/PD 2026 (Copenhagen).
• New analyses highlighted include data stratified by plasma pTau181 subset that the company says demonstrate a greater treatment effect with reduced likelihood of Alzheimer’s disease co‑pathology.
• The filing also references new PK/PD (pharmacokinetic/pharmacodynamic) analyses of the Phase 2b data.
• Presentation materials are available on the company website and may be used in investor/analyst presentations; Exhibit 99.1 attached to the 8-K.

Why It Matters
These disclosures provide investors an early look at additional clinical analyses that could affect the perceived therapeutic potential and development path for neflamapimod in DLB, especially if benefit appears stronger in patients with lower likelihood of AD co‑pathology. The AD/PD conference presentation will be a near-term catalyst for more detailed data and market reaction. The 8-K does not include financial results or formal regulatory filings; investors should watch for the conference presentation, any peer‑reviewed data releases, and subsequent SEC filings for fuller context.